belinostat + erlotinib

Belinostat + erlotinib is a combination of two small molecule anticancer agents with distinct mechanisms of action. Belinostat is a histone deacetylase (HDAC) inhibitor that induces cell cycle arrest, apoptosis, and inhibition of angiogenesis by preventing the removal of acetyl groups from lysine residues on histones and non-histone proteins, leading to increased expression of tumor suppressor genes[1][4][6]. Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling pathways involved in cancer cell proliferation and survival[2][3][5]. Both drugs are approved individually for various cancers; belinostat for relapsed or refractory peripheral T-cell lymphoma, and erlotinib for metastatic non-small cell lung cancer with specific EGFR mutations as well as advanced pancreatic cancer. The combination may be explored in research settings to target multiple oncogenic pathways.

Other names

none